Corticosteroid-impairment of healing and gastric pentadecapeptide BPC-157 creams in burned mice

Pentadecapeptide BPC 157 (PL 14736) improves ligament healing in the rat

“…Under the most severe conditions of transected ligament, with BPC 157 mg-ng-regimens given alone intraperitoneally, per-orally and topically, dose-regimens and application methods that had been successfully used before [1][2][3][4][5][6][7][8][9][10][11][12] and in time, the healing process on an acute ligament injury may convert rapidly from a failure to a success and all healing improvements. Function in either condition, normal (walking rats) and stressed (running rats), biomechanic, macro/microscopy were noted superior as before [1][2][3][4][5][6][7][8][9][10][11][12] in tendon studies 1,2,10 and other wound studies, 4,9,10,12 , not species related.…”

“…1419), a partial sequence of human gastric juice protein BPC, peptide with 99% (HPLC) purity, freely soluble in water at pH 7.0 and in saline, dose ranges and ways of application as previously 1,2,[4][5][6][7][8][9][10][11]13 dissolved in saline, as follows: (i) BPC 157 10 mg or 10 ng/kg or saline 5.0 ml/kg (controls), intraperitoneally, or (ii) BPC 157 in neutral cream (1.0 mg dissolved in distilled water/g commercial neutral cream) or commercial neutral cream (controls), as a thin layer, locally, at the site of injury, administered once daily with the first application 30 min after surgery and the final application 24 h before sacrifice; (iii) BPC 157 0.16 mg/ml or nothing (controls) in the drinking water (12 ml/day/rat) until sacrifice.…”

“…The assessment (based on markedly reduced (the MCL failed) experimental, injured side (E) compared with the normal, uninjured side (N) 9,14,15 ) was on days 1, 3, 5, 7, 10, 14, 21, 28, 60, and 90 following transection: (i) walking recovery index (WRI) of permanently tottering walk as the foot print length (PL) difference (D, mm) NPL-EPL in spontaneously walking and running rats; (ii) Koka's extensor postural thrust (EPT)-motor function index (MFI) as the amount of weight borne at the moment when, the rat held upright with the hind limb extended and placed upon a digital weighing scale (precision 0.001 g) begins to bear weight on the scale (NEPT-EEPT)/ NEPT; (iii) contracture of operated experimental leg (EL) as failed knee extension in relation to the uninjured leg (NL) as difference (D, mm) NL-EL at the moment when one examiner pulled the back legs to achieve a maximum knee joint extension while the other examiner marked a sign on the uninjured leg at the place reached by the thumb of the operated leg. The distance between the marked sign and top of the rats thumb was measured by roller rules; (iv) valgus instability, gross functional instability was assessed by turning from below the rats walking and running in a confined tunnel with transparent bottom.…”

“…We introduced intraperitoneal, per-oral (in drinking water) and topical (thin cream layer) peptide therapy always given alone, without a carrier, using stable gastric pentadecapeptide BPC 157 (GEPPPGKPADDAGLV) (for review, see Refs. [1][2][3][4][5][6][7][8][9][10][11][12] ). Previously, as an anti-ulcer peptide stable in human gastric juice [4][5][6][7][8][9] BPC 157 was effective in inflammatory bowel disease therapy (PL 14736) (no toxicology reported (for review, see Ref.…”

“…Also, BPC 157 particularly improved healing of transected tendon and muscle 1,2,10,11 and wound healing effect including the expression of the early growth response 1 (egr-1) gene (but also its repressor nerve growth factor 1-A binding protein-2 (nab2)). [4][5][6]9,10,12,13 Therefore, such peptide's capabilities [1][2][3][4][5][6][7][8][9][10][11][12] and responsibility for cytokine and growth factor generation and early extracellular matrix (collagen) formation may provide a peptide therapy effective functionally, biomechanically, macroscopically, and microscopically, [1][2][3][4][5][6]9,10,12,13 and thereby, suitable to improve ligament healing.…”